Відмінності між версіями «Le disease in peripheral blood or bone marrow even when»

Матеріал з HistoryPedia
Перейти до: навігація, пошук
м
м
 
(не показані 9 проміжних версій 4 учасників)
Рядок 1: Рядок 1:
−
These sufferers are viewed as to have achieved a minimal residual illness (MRD) negative status.17-20 Various phase II trials have demonstrated that sufferers reaching MRD negativity have a signif-icantly longer survival than people that stay MRD optimistic, and that is true for patients treated with conventional chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 In addition, a phase III trial performed by the German CLL Study Group (GCLLSG) not too long ago revealed that sufferers getting MRD negativity had drastically longer progression-free and overall survivals, irrespectively in the therapy received.18 Unfortunately, nonetheless, some of these research have been flawed by inappropriate statistical evaluation, specifically the measurement of time-to-event outcomes from treatment initiation.27 Moreover, there are many caveats to the use of MRD evaluation in sufferers with CLL.28 First, CLL remains incurable and at the least 30  of sufferers who achieve MRD negativity just after front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC at some point practical experience a disease relapse within five years.18 Secondly, unlike the scenario in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there is certainly no formal proof of a therapeutic benefit of re-treatment upon [http://www.medchemexpress.com/STF-62247.html STF 62247 site] documentation of MRD positivity immediately after an initial MRD-negative response in comparison to therapy at the time of clinical relapse. These sufferers are viewed as to have achieved a minimal residual disease (MRD) damaging status.17-20 Quite a few phase II trials have demonstrated that individuals attaining MRD negativity possess a signif-icantly longer survival than individuals who remain MRD positive, and that is correct for patients treated with conventional chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 In addition, a phase III trial performed by the German CLL Study Group (GCLLSG) recently revealed that individuals acquiring MRD negativity had substantially longer progression-free and all round survivals, irrespectively with the treatment received.18 Sadly, even so, a few of these research have been flawed by inappropriate statistical analysis, especially the measurement of time-to-event outcomes from treatment initiation.27 Moreover, there are lots of caveats for the use of MRD analysis in patients with CLL.28 Initial, CLL remains incurable and a minimum of 30  of patients who attain MRD negativity after front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC sooner or later experience a illness relapse inside five years.18 Secondly, unlike the situation in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there is no formal proof of a therapeutic benefit of re-treatment upon documentation of MRD positivity soon after an initial MRD-negative response when compared with remedy at the time of clinical relapse. In fact, very couple of studies have demonstrated a clear benefit from MRD eradication or consolidation therapy in CLL,31,32 and some on the strategies tested, even though effective, resulted in important toxicity.33-35 Thirdly, it might be argued that MRD assessment is basically a surrogate for evalution of other adverse prognostic markers due to the fact, for example, sufferers with a 17p014 Ferrata Storti Foundation. That is an open-access paper. doi:10.3324/haematol.2013.099796 The on the web version of this article has a Supplementary Appendix. Manuscript received on October 17, 2013. Manuscript accepted on December 31, 2013. Correspondence: jdelgado@clinic.ub.eshaematologica | 2014; 99(5)R. Santacruz et al.deletion possess a greater probability of remaining MRD-positive just after therapy in comparison to sufferers with no this chromosome abnormality.18 For all these causes, existing guidelines for the management of individuals with CLL propose MRD assessment only inside clinical trials with "curative intention".36 With all this information in mind, we retrospectively evaluated the impact of MRD around the outcome of sufferers with CLL receiving any front-line therapy inside the context of an incredibly detailed prognostic evaluation, like not too long ago described recurrent gene mutations.survival and general survival had been calculated employing a landmark evaluation. All calculations had been performed using either SPSS, version 18.0, or R, version 3.0.1. Two-sided P values 0.05 had been thought of statistically significant. A detailed explanation from the statistical strategies is offered within the On the internet Supplement.Benefits Baseline characteristicsThe median age from the entire cohort was 58 years (variety, 27-93 years), as well as the percentage of individuals older than 70 years was 22 .
+
Santacruz et al.deletion possess a larger probability of remaining MRD-positive after therapy when compared with sufferers without this chromosome abnormality.18 For all these reasons, existing suggestions for the management of individuals with CLL suggest MRD assessment only inside clinical trials with "curative intention".36 With all this facts in thoughts, we retrospectively evaluated the effect of MRD on the outcome of sufferers with CLL getting any front-line therapy within the context of a very detailed prognostic evaluation, like not too long ago described recurrent gene mutations.survival and all round survival were calculated using a landmark analysis. All calculations have been performed making use of either SPSS, version 18.0, or R, version 3.0.1. [http://brycefoster.com/members/coughguide59/activity/704540/ Et al. 2011) (Vagnarelli and Earnshaw 2012) together with] Two-sided P values 0.05 had been regarded statistically considerable. A detailed explanation of your statistical strategies is obtainable within the On the net Supplement.Final results Baseline characteristicsThe median age from the whole cohort was 58 years (variety, 27-93 years), and also the percentage of individuals older than 70 years was 22 .Le illness in peripheral blood or bone marrow even when incredibly sensitive immunophenotypic or molecular strategies are utilized to look for residual disease. These patients are regarded as to possess accomplished a minimal residual illness (MRD) damaging status.17-20 Several phase II trials have demonstrated that patients achieving MRD negativity possess a signif-icantly longer survival than people who stay MRD constructive, and this can be accurate for sufferers treated with conventional chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 Moreover, a phase III trial performed by the German CLL Study Group (GCLLSG) not too long ago revealed that individuals obtaining MRD negativity had substantially longer progression-free and overall survivals, irrespectively of the remedy received.18 Sadly, even so, some of these studies have been flawed by inappropriate statistical analysis, specifically the measurement of time-to-event outcomes from therapy initiation.27 Additionally, there are lots of caveats to the use of MRD evaluation in patients with CLL.28 First, CLL remains incurable and no less than 30  of patients who obtain MRD negativity immediately after front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC eventually practical experience a disease relapse inside five years.18 Secondly, unlike the situation in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there is certainly no formal proof of a therapeutic benefit of re-treatment upon documentation of MRD positivity following an initial MRD-negative response in comparison to treatment in the time of clinical relapse. In actual fact, pretty handful of studies have demonstrated a clear benefit from MRD eradication or consolidation therapy in CLL,31,32 and a few with the methods tested, despite the fact that powerful, resulted in important toxicity.33-35 Thirdly, it may very well be argued that MRD assessment is simply a surrogate for evalution of other adverse prognostic markers considering the fact that, for example, individuals having a 17p014 Ferrata Storti Foundation. This is an open-access paper. doi:ten.3324/haematol.2013.099796 The on line version of this article includes a Supplementary Appendix. Manuscript received on October 17, 2013. Manuscript accepted on December 31, 2013. According to D ner's hierarchical model, 17/221 (8 ) and 40/221 (18 ) sufferers had 17p deletion and 11q deletion, respectively.

Поточна версія на 22:28, 9 лютого 2018

Santacruz et al.deletion possess a larger probability of remaining MRD-positive after therapy when compared with sufferers without this chromosome abnormality.18 For all these reasons, existing suggestions for the management of individuals with CLL suggest MRD assessment only inside clinical trials with "curative intention".36 With all this facts in thoughts, we retrospectively evaluated the effect of MRD on the outcome of sufferers with CLL getting any front-line therapy within the context of a very detailed prognostic evaluation, like not too long ago described recurrent gene mutations.survival and all round survival were calculated using a landmark analysis. All calculations have been performed making use of either SPSS, version 18.0, or R, version 3.0.1. Et al. 2011) (Vagnarelli and Earnshaw 2012) together with Two-sided P values 0.05 had been regarded statistically considerable. A detailed explanation of your statistical strategies is obtainable within the On the net Supplement.Final results Baseline characteristicsThe median age from the whole cohort was 58 years (variety, 27-93 years), and also the percentage of individuals older than 70 years was 22 .Le illness in peripheral blood or bone marrow even when incredibly sensitive immunophenotypic or molecular strategies are utilized to look for residual disease. These patients are regarded as to possess accomplished a minimal residual illness (MRD) damaging status.17-20 Several phase II trials have demonstrated that patients achieving MRD negativity possess a signif-icantly longer survival than people who stay MRD constructive, and this can be accurate for sufferers treated with conventional chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 Moreover, a phase III trial performed by the German CLL Study Group (GCLLSG) not too long ago revealed that individuals obtaining MRD negativity had substantially longer progression-free and overall survivals, irrespectively of the remedy received.18 Sadly, even so, some of these studies have been flawed by inappropriate statistical analysis, specifically the measurement of time-to-event outcomes from therapy initiation.27 Additionally, there are lots of caveats to the use of MRD evaluation in patients with CLL.28 First, CLL remains incurable and no less than 30 of patients who obtain MRD negativity immediately after front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC eventually practical experience a disease relapse inside five years.18 Secondly, unlike the situation in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there is certainly no formal proof of a therapeutic benefit of re-treatment upon documentation of MRD positivity following an initial MRD-negative response in comparison to treatment in the time of clinical relapse. In actual fact, pretty handful of studies have demonstrated a clear benefit from MRD eradication or consolidation therapy in CLL,31,32 and a few with the methods tested, despite the fact that powerful, resulted in important toxicity.33-35 Thirdly, it may very well be argued that MRD assessment is simply a surrogate for evalution of other adverse prognostic markers considering the fact that, for example, individuals having a 17p014 Ferrata Storti Foundation. This is an open-access paper. doi:ten.3324/haematol.2013.099796 The on line version of this article includes a Supplementary Appendix. Manuscript received on October 17, 2013. Manuscript accepted on December 31, 2013. According to D ner's hierarchical model, 17/221 (8 ) and 40/221 (18 ) sufferers had 17p deletion and 11q deletion, respectively.

Отримано з http://istoriya.soippo.edu.ua/index.php?title=Le_disease_in_peripheral_blood_or_bone_marrow_even_when&oldid=286147